EXAI (Exscientia) רווח למניה בארבעת הרבעונים האחרונים

Exscientia plc (EXAI) operates robotic AI laboratories in Oxford for high-precision synthesis. Revenues are based on platform licensing and partner milestone payments for research stages. The trailing twelve months (ttm) net income per share growth rate reflects market dynamics, where the value -38.70 indicates the asset's status. The company is currently accelerating the development of its own oncology drugs through clinical trials.

For Exscientia plc (EXAI), which invests in AI-driven drug discovery, earnings per share dynamics serve as a critical indicator of financial stability. An analysis of the year-over-year EPS (TTM) change measures the net income growth rate over a rolling year relative to the previous period. This metric provides a real-time assessment of capital management efficiency. For a company with high R&D cash burn, this chart demonstrates a dependence on partner payments. It is essential for investors to track this trend to evaluate the asset's solvency.